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DISCUSSION OF HEPATOTROPHIC 
FACTORS AND REGENERATION 
I' 
Thomas E. Starzl, M.D., Ph.D. and Charles W. Putnam, M.D. 
Until about a decade ago, dogma supported by the pUblications of 
Child [1] and Fisher [2] and many others held in what has been termed 
the flow hypothesis, that the quantity of portal blood was the only 
important hepatotrophic influence, and that the quality of this portal 
blood was of no real significance in the maintenance or restoration of 
hepatic mass. As Schindler mentioned earlier this afternoon, this concept 
has been seriously weakened, if not overthrown, by a series of 
investigations with what can be loosely termed double liver fragment 
preparations, which models, incidentally, were originally evolved without 
any real consideration at all for studying regeneration. I would like to 
present this information to you now, with an apology for the lack of 
sophistication which it obviously has in relation to much of the other 
work you have heard about today. Yet, what I have to say undoubtedly 
has a relation to regeneration. In particular I am intrigued with the 
possible relationship of our studies to Professor Weber's presentation. 
The first experiment was with auxiliary liver transplantations to 
immunosuppressed canine recipients, using portal revascularization with a 
technique (Fig. 1) by which the portal vein was given blood flow from the 
inferior vena cava [3] . Arterialization was from the aorta or iliac artery. 
The native liver retained its natural vascularization. 
In spite of the fact that the blood flow to this kind of auxiliary 
transplant has been shown to be greater than to the native liver [4] , the 
extra organs undergo fantastic atrophy [3]. The atrophy in turn can be 
prevented if the portal flow is given to the transplant, depriving the host 
liver of this source of blood supply [5]. 
Later, the more satisfactory model shown in Fig. 2 was used, dividing 
the animal's own liver into 2 components. Unlike auxiliary transplanta-
tion, the split liver preparation avoided the situation in which one of the 
liver fragments was under immunologic attack, whereas the other was not. 
The split liver technique consisted of detaching one of the portal branches 
and connecting it to the inferior vena cava, whereas the other liver 
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Fig. 1. Auxiliary liver transplantation in dogs. Note that the reconstituted portal 
blood supply is from the distal inferior vena cava. Cholecystoduodenostomy is 
performed. (By permission of Ann Burg 160:411, 1964.) 
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Fig. 2. Partial portacaval transposition. The entire vena caval flow is directed into 
either the left (A) or the right (B) portal venous branch, while the contralateral liver 
lobes continue to receive splanchnic venous blood. (By permission of Surg Gynec 
Obstet 137:179, 1973.) 
fragment received a natural blood supply. Under these conditions, the side 
which was given vena cava blood flow, even though this flow was greater 
than on the other side, invariably underwent profound atrophy and was 
found to be in a state of relative hypoplasia and deglycogenation. The 
glycogenation, hypertrophy and hyperplasia on the side getting splanchnic 
venous blood were imputed to exposure of these hepatocytes to some 
unspecified component(s) of the splanchnic venous blood, which was 
(were) speculated to be largely removed by one passage through the 
liver [3, 5, 6, 7]. 
In an effort to learn the nature of these hepatotrophic factors, we 
recently published [8] a series of observations with a canine preparation 
which divides the splanchnic venous return into two compartments (Fig. 
3). One portion of the liver is perfused by intestinal venous blood going 
through a vein graft to either the right or left portal branch. The other 
liver lobes received blood from the pancreaticogastroduodenosplenic area. 
Liver fragments receiving the hormone-rich blood from the upper 
abdominal organs flourished. The glycogen content of these cells was 
greater. The size of the hepatocytes were increased, as could be 
quantitated with a technique developed by Dr. K. A. Porter of London, in 
which the liver cell images were cut out and weighed (Fig. 4). 
In the deceptive original title of my discussion, particular reference was 
made to cyclic AMP. This phase of our investigation was designed to 
either support or deny the hypothesis I just implied, that trace quantities 
of pancreatic hormones were the principal hepatotrophic substances in 
portal blood. This was done by measuring cyclic AMP concentrations and 
the production of cyclic AMP in the two sides of the liver fragments 
which had differing blood supplies, as shown in Fig. 2 and 3, under a 
variety of conditions. Numerous other biochemical determinations were 
also done by my colleague Dr. Francavilla of Bari, Italy, including 
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Fig. 3. Technique of division of splanchnic venous flow into a pancreatico·gastro-
duodenal-splenic compartment and an intestinal compartment. Blood from these 
respective sources is directed into the right or left lobes. The tail of the inferior lobe of 
the pancreas was resected since it drains separately into the mesenteric vein. (By 
permission of Surg Gynec Obstet 137:179, 1973.) 
LEFT RIGHT 
Fig_ 4. Hepatocyte shadows traced during histopathologic examination. These were 
later cut out on standard paper and weighed as an index of hepatocyte size. The 
specimens depicted were from the experimental Group 2 (see Fig. 3A). The right lobes 
with the large hepatic cells received venous blood from the pancreas, stomach, 
duodenum and spleen. The relatively shrunken left lobes with the small hepatocytes 
received intestinal blood. (By permission of Surg Gynec Obstet 137:179, 1973.) 
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quantitative glycogen, phosphorylase, glucokinase and protein synthesis, 
just to mention a few. I will not bother you with the details of our results 
which, as I mentioned, have been published [8], except to say that there 
was a major biochemical, apparently hormone directed, dissociation 
between the two sides of the liver. The preparation I would like to briefly 
allude to is the one (Fig. 2) in which the entire splanchnic flow goes to 
one side and the vena caval flow to the other side of the liver. In Fig. 5 is 
shown a pilot experiment done on normal dogs. These animals were given 
intravenous tolbutamide, which generates a marked increase in insulin 
concentration in the portal vein, but has very little change in the systemic 
venous insulin levels. Hepatic cyclic AMP is essentially unchanged. Since a 
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Fig. 5. Changes in peripheral and portal venous insulin and hepatic cyclic 3', 
5' ·adenosine monophosphate, cyclic AMP, occurring in a normal dog infused with 
tolbutamide. Note that the peak insulin response in the portal blood occurred 25 to 40 
minutes after infusion· and that no significant alterations in hepatic cyclic 3', 
5'·adenosine monophosphate were caused acutely by the tolbutamide itself. (By 
nermission of Surg Gynec Obstet 137: 179, 1973.) 
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small decrease in hepatic cyclic AMP would be impossible to measure 
biochemically, the effect of the tolbutamide-induced insulin on cyclic 
AMP was magnified by a40 giving glucagon, which, unopposed, produces 
a tremendous increase in liver cyclic AMP, but when opposed by insulin, 
gives a cyclic AMP pattern similar to control animals. When the 
preparations shown in Fig. 2 were studied with the tolbutamide-glucagon 
test, the lobes receiving splanchnic blood (Fig. 6-panels on the left) had a 
response similar to normal dogs, whereas the contralateral lobes supplied 
by vena caval blood (Fig. 6-paneis on the right) showed a rapid 
accumulation of cyclic AMP. From this and other experiments, we have 
concluded that the hepatotrophic factors in splanchnic venous blood are 
trace quantities of hormones, the master anabolic hormone being insulin, 
counterbalanced to an unknown extent by catabolic hormones including 
glucagon. epinephrine and probably others as well. 
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Fig. 6. Results of tolbutamide-giucagon tests in eight dogs with partial portacaval 
transposition (Fig. 2), demonstrating the effect of endogenous insulin in the lobes 
receiving splanchnic venous blood. These insulin-controlled lobes had a restrained 
cyclic 3', 5'·adenosine monopbosphate response to the exogenous glucagon, whereu 
the response in the other lobes was uninhibited. (By permission of Surg Gynec Obstet 
137:179,1973.) 
"', 
Hepatrophic Factors and Regeneration 175 
What has this to do with regeneration? From the old-fashioned measures 
of mitotic indices in our early publications, we have thought for almost a 
decade that the hepatotrophic factors subserve hyperplasia as well as 
hypertrophy and are, therefore, central to a full understanding of 
regeneration. These contentions have been bolstered by confirmatory data 
with DNA synthesis, as measured by thymidineAncorporation in rats, by 
Chandler, Lee and Orloff [9] of San Diego about 5 years ago, and, more 
recently, by Fisher [10]. We ourselves have made thymidine incorpora-
tion studies in our split liver preparations. When all the splanchnic flow 
goes to one side and the vena cava flow to the other side, a few days after 
the operation, there is invariably a greater thymidine uptake in the 
splanchnic-fed lobes. After some 60 or 70 days, this differential goes 
away, but can be restored with a 40% resection of the liver. It is 
interesting that the differential can be eliminated or blunted by a total 
pancreatectomy. With the procedure dividing the splanchnic flow into 
intestinal and pancreatic components (Fig. 3), the differential favors the 
pancreatic side, as opposed to the liver lobes receiving intestinal blood. 
These findings are consistent with the hypothesis that pancreatic 
hormones are important hepatotrophic factors and are related to 
regeneration. This conclusion is, of course, directly contrary to the claims 
by Price et al. [11] that hypertrophy and hyperplasia, as affected by 
splanchnic hepatotrophic factors, are in inverse relation to each other; it is 
also contrary to the recent opinions of Fisher [12], who has claimed that 
the hepatotrophic factors are of intestinal origin and are probably related 
to folic acid or vitamin B12 from the ileum. 
Be that as it may, it seems probable that the hepatotrophic concept is a 
central but incompletely recognized fact of liver physiology, which, when 
completely worked out, should help reconcile a number of previously 
divergent opinions about such diverse matters as the explanation for liver 
regeneration (as we have heard from Professor Weber today), the origin of 
portaprival syndromes, optimum conditions for auxiliary liver transplanta-
tion and the reasons for the dramatic benefits of portal diversion 
procedures for patients with glycogen storage disease or idiopathic type II 
hyperlipoproteinemia, to cite only a few examples. 
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DISCUSSION 
WEINBREN: I noticed that in your technical preparation the blood 
coming from the intestine always went through a graft to one side of the 
liver, and the blood coming from the pancreas did not; it went directly to 
the liver. Knowing how delicate the portal pressures are, I was wondering 
perhaps if the graft caused some obstruction to flow and that part of the 
liver, as a result, was disfavored. The atrophy was related to the fact that 
the blood went through the graft and the hypertrophy on the other side 
was related to the atrophy that was produced by the blood going through 
the graft. It seems to me that in order to avoid this criticism, perhaps the 
graft should. have been alternated between the two sides, that is the 
intestinal and pancreatic sources. At the moment, I cannot see how the 
one hypothesis is better than the other one, although you may well be 
right. 
STARZL: I'm sorry that that paper (Starzl, T.E., Francavilla, A., 
Halgrimson, C.G., Francavilla, F.R., Porter, K.A., Brown, T. and Putnam, 
C.W.: The origin, hormonal nature and action of portal venous hepato· 
trophic substances. Surg Gynec Obstet 137:179, 1973) hasn't gotten over 
here yet, but we did it both ways, precisely for the reason you mentioned. 
No matter which way the vein graft went (right versus left), the results 
were as I described. 
HOLZER: Was this mentioned in your abstract here? 
STARZL: No, it was not. 
WEBER: I have a piece of information which might be helpful to Dr. 
Starzl. If you measure thymidine metabolism in the diabetic rat, there is a 
dramatic decrease of incorporation of thymidine into DNA and also, in a 
minor degree, of the degradation of thymidine. When you treat diabetic 
rats with insulin, there is, as you know, an enlargement of the liver, and 
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there is a very marked rise in the incorporation of thymidine into DNA. In 
2 to 3 days, this becomes a very marked overshoot, the type of thing you 
observe in glucose 6-phosphate dehydrogenase. The catabolic pathway 
climbs up rather sluggishly. There is one other paper on this matter. This 
was published by Weber et al. in Advances in Enzyme Regulation, Vol. 10, 
pp. 39-62, 1972 and I refer to it in the Israeli Journal of Medicine, 
(8:325-342, 1972) at the Insulin Conference and the 50th anniversary of 
its discovery, so this was 1972. There is another"paper which you should 
also keep in mind, Younger et al. (Cancer Res 26:1408-1414, 1966), on 
the action of insulin on stimulating the incorporation of thymidine into 
DN A. Younger and his groups counted mitotic figures, which were 
increased after insulin administration. They also determined DNA 
polymerase; these two lines of evidence favor insulin having a role in this 
process, along with many other things. 
STARZL: I'm a little hesitant to talk about preliminary work, but we 
have, of course, gone ahead with other experiments. We are now working 
with alloxan diabetic dogs and dogs submitted to total pancreatectomy 
and followed chronically. It has seemed to me that there is a rather 
different effect of total pancreatectomy, compared to the insulinopenic 
effect of alloxan diabetes in animals with the split transposition (see Fig. 
2) or splanchic division (Fig. 3). Two months after total pancreatectomy, 
the two liver sides are quite different. The side that is deprived of all 
splanchic flow becomes grossly waxy and is laden with fat. Such changes 
are less marked in animals with alloxan diabetes. Our conclusion has been 
that there is a very major difference between a mere insulinopenia and the 
more complex loss of total pancreatectomy. This would suggest that the 
hepatotrophic substances are multiple interlocking factors. 
I would also like to comment on the question of both flow and oxygen 
content. The flow in these preparations, in which there has been withering 
of the nonsplanchic side, has usually been shown to be greater than in the 
other side, at least early after operation. We have also carried out an 
experiment in which we arterialized one branch of the portal vein, so that 
the flow to that side was not only many times greater than to the other 
side, but it also had greater oxygen content. These advantages did not save 
the liver fragment deprived of splanchic venous blood, which underwent 
atrophy. 
Parenthetically, it has been accepted in the literature for many years 
that portal venous blood has a high oxygen content compared to vena 
caval blood. I don't know the origin of this belief. We published a small 
paper a few years ago, in which we examined precisely this question. In 
awake dogs, after we placed in-dwelling catheters in the portal vein and 
suprarenal vena cava, there was no difference in oxygen concentration 
between the portal venous and vena caval blood (Hermann, T.J., Taylor, 
P.D., Marchioro, T.L. and Starzl, T.E.: Oxygen and C02 content in the 
splanchic and nonsplanchic blood of dogs with portacaval transposition. 
Surgery 60:1229, 1966). 
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RABES: I have just a short remark on the action of insulin in vitro. We 
succeeded in cultivating liver cells of new-born rats: they grow very fast if 
insulin is added to the medium. 
MOLIMARD: I would like to know if you investigated the possibility of 
modifying the external pancreatic secretion, because the absorption in the 
upper part of the gut is normally very high and the blood from the 
pancreas and the upper part of the intestine might normally convey to the 
liver some nutriments it has to cope with. Did you investigate the 
possibility? 
STARZL: I think you have raised two possible questions. First, do the 
upper intestinal organs emit blood with a higher oxygen concentration 
than the lower ones? That is probably true, but I do not think that the 
oxygen is the critical hepatotrophic factor for the reasons I mentioned a 
few moments ago. Second, as to their being other possibilities than 
insulin, I have already conceded that, and indeed believe that inter-
relationships between multiple hormones and, even nutlients, explain the 
hepatotrophic effect. Certainly, however, insulin is a key hepatotrophic 
factor, as both Professor Weber and Prof. Rabes have suggested. In this 
connection, I would like to call your attention to a nice paper by Reaven, 
E.P., Peterson, D.T. and Reaven, G.M.: The effect of experimental 
diabetes mellitus and insulin replacement on hepatic ultrastructure and 
protein synthesis (J Clin Invest 52:248-262, 1973), in which is described 
the very striking depletion of rough endoplasmic reticulum in hepatocytes 
and other major changes, which occur very quickly after the creation of 
the state of insulinopenia. Their controls showed that it wasn't the alloxan 
per se that was responsible, but rather, the insulin deprivation. 
With your permission, may I tell you about one either extremely 
interesting observation that has been made in humans a few months ago. 
This concerns the treatment of a 12-year-old child with homozygous type 
II idiopathic hyperlipoproteinemia, a disease that responds poorly to 
medical therapy. Our patient had a serum cholesterol concentration of 
almost 1000 mgm%. We speculated that the diversion of the pancreatic 
hormones and other hepatotrophic effects away from the liver might tum 
off lipoprotein synthesis. We performed end "to-side portacaval shunt as a 
last resort, because the child had had a myocardial infarction and was in 
intractable heart failure from aortic stenosis, apparently due to xanthoma 
in the valve. After the operation, the visible superficial xanthoma, which 
characterize the disease, began to flatten within a few days, and her angina 
disappeared. Her heart problem went away and the serum cholesterol 
dropped from 1000 down to about 230 mgm%. She had a liver biopsy 6 
months after the shunt operation, and the changes I described in Reaven's 
study were found in the liver. The profound benefit from the portacaval 
shunt again illustrates the specificity of the portal venous blood and the 
striking metabolic effects of its diversion in certain disease states. The 
report of this case was published (Starzl, T.E., Chase, H.P., Putnam, C.W. 
and Porter, K.A.: Portacaval shunt for the treatment of hyperlipo-
proteinemia. Lancet 2:940,1973). 
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DATIA: I have understood that portal blood, when diverted, acts as a 
promoter of regeneration, and it has been postulated that possibly 
something coming from the pancreas, an insulin-like material, is operating 
here. Now my question is, even if we are diverting the blood, the insulin 
or the insulin-like materials still go into systemic circulation, i.e. the 
hepatic artery, which supplies the hepatocytes."Hence, diversion of blood 
should not make much difference. In other words, are we saying that only 
the portal side is important for this phenomena? 
The second clinical observation we made was with extra hepatic portal 
vein 0 bstruction, in which it is assumed that the portal vein is more or less 
occluded and the blood supply is from the arterial side. Even in this 
situation, the liver, at least in our Chandigarh series, had been of normal 
weight. 
STARZL: To answer his question in a summary, I would say that when 
one uses the so-called double liver fragment models, it is possible to 
demonstrate that the two fragments live in different chemical worlds and 
that those worlds are, as far as we can tell, dominated mainly by hormone 
influences. The use of the double liver fragment model was the main 
breakthrough, technically making it possible to study hepatotrophic 
substances. The reason was exactly that stated by the gentlemen from 
India. If you divert portal blood in an animal with a single liver, the 
changes that are created in this liver, while real, are very subtle, and they 
are difficult to study because there is the recirculation effect that was just 
described. This is why Eck fistula has been the cause of so much 
controversy and why Child's so-called portal-caval transposition has 
created more confusion than it has shed light. In Child's transposition, the 
recirculation to the liver would occur roughly in proportion to total 
hepatic blood flow. In tum, this would explain why the transposition 
procedure protects the liver, because it recirculates more effectively than 
is the case with Eck fistula. But as I have alread.y stated, while the effects 
of portal diversion may be subtle because of this recirculation, they are 
real, even when there is a single liver, and even when there is recirculation, 
as in the astonishing outcome of our child with hyperlipidemia indicates. 
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exclusive primary control to agents specifically provided by portal blood 
now seems at least open to question. On the other hand, since 
regeneration is delayed, and possibly somewhat diminished in the absence 
of portal blood and portal splanchnic organs, portal blood factors must at 
the very least have a facilitating or enhancing role; whether insulin and 
glucagon, as proposed by Dr. Starzl, and other portal blood components 
as well, can still exert primary control over the growth process at the 
reduced levels prevalent in eviscerated animals seems questionable, but 
cannot be excluded without further study. We have not yet studied 
glucagon sufficiently to warrant any discussion of its effects. 
DISCUSSION 
WEBER: I would like to comment on the paper by Dr. Bucher, because I 
think what she presented is of major importance for liver regeneration and 
for our own studies. I think that the elegant method that Dr. Bucher 
developed indeed opened the door to decisive experiments to determine 
factors that play a role in unleashing the regenerating liver process. I do 
think that she might have eliminated the insulin quite effectively. There is 
one paper which might be consulted that you might have already looked 
at. This is by Carl Morgan, who examined induction of insulinase in the 
liver by insulin over period of time. I believe this would confirm your 
suggestion that the circulating insulin, but not necessarily the liver-bound 
insulin, would be removed effectively from the animal. In that case, you 
would have an insulin-free animal. So I think what you are reporting is of 
very great importance, indeed. 
BUCHER: Thank you, Dr. Weber, for your kind remarks. We think that 
the circulating insulin is probably very low at the time of the partial 
hepatectomy in the eviscerated animals. This is confirmed in a preliminary 
way by measurements of portal blood insulin, but they are still too few to 
be really significant. There remains the possibility that insulin could be 
bound by the liver in a cumulative fashion. Dr. Leffert, who works with 
liver cell cultures in Dr. Holley's laboratory at the Salk Institute, 
mentioned, at a Gordon Conference last summer, that large scale hepatic 
binding of insulin occurs within minutes after a partial hepatectomy. 
Obviously, we must look into that further before I can make any positive 
assertions; we are simply presenting this information as an attempt to 
eliminate certain variables, and to obtain a system that r hope will be 
useful to ourselves and others. 
STARZL: r would just like to congratulate Dr. Bucher on a marvelous 
study, some of which she was kind enough to send me several months ago. 
r think it might be an error to consider that insulin, or anything else for 
that matter, is not an hepatotrophic factor on the basis that its absence 
does not cause death or that its absence does not cause a complete 
cessation of DNA synthesis. Doctor Bucher's skepticism about hepato-
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trophic factors is based on the finding that regeneration can occur after 
evisceration. Yet, to me, what is really significance about her data is that 
the response to hepatectomy is thereby so greatly reduced, and very 
probably delayed as well. To these striking effects. insulinopenia and 
other factors doubtless c0l2tributed. 
In searching for implications of these findings, let me mention one 
which might be of interest to those interested in oncology. It can be 
illustrated by a paper by Heuson and Legros (Cancer Res 32:226, 1972) 
which confirms many previous similar publications about the effect of 
insulinopenia on tumor growth. What was done in Heuson and Legros' 
study was to evaluate what alloxan diabetes did to the expected growth of 
a chemically induced rat mammary carcinoma. The diabetes inhibited the 
growth of the tumor. 
Heuson and Legros also did a corollary study in which they determined 
which of those animals carried tumors that were dependent on insulin for 
vigorous growth in tissue culture (not merely survival but vigorous 
growth). They found that the tumors from animals that were responders 
to alloxan diabetes, in that growth was inhibited, were the same tumors 
that required insulin in the tissue culture for vigorous growth. 
This situation may be analogous to that of hepatic regeneration in that 
insulin may play an important permissive role. In either situation, an all or 
none attitude about factors which promote or permit cell replication does 
not seem justified, nor should factors be dismissed as trivial merely 
because their absence fails to cause total cessation of cell division. 
BUCHER: I did not mean to imply that insulin has no function in liver 
growth. I am sure it does; we all know that it is necessary for survival of 
the animal, and that probably applies to the liver cells as well. TI:le 
question we are asking is whether insulin can serve as the single dominant 
agent regulating liver growth, or, alternatively, whether it has a mere 
permissive or enhancing role, acting in conjunction with some other 
agents. The evidence so far favors the nondominant status. This may be an 
oversimplification. No doubt there are many factors here; we are simply 
attempting to sort them out. 
